
Andrew S Davison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/239718/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Molecular Genetics and Metabolism, 2018, 125, 127-134.	0.5	89
2	Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 762-772.	5.5	78
3	Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. Metabolomics, 2022, 18, 6.	1.4	60
4	Urine homogentisic acid and tyrosine: Simultaneous analysis by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 106-112.	1.2	54
5	Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Annals of Clinical Biochemistry, 2015, 52, 597-605.	0.8	46
6	The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Annals of Clinical Biochemistry, 2017, 54, 323-330.	0.8	39
7	Comparison of eight routine unpublished LC–MS/MS methods for the simultaneous measurement of testosterone and androstenedione in serum. Clinica Chimica Acta, 2016, 454, 112-118.	0.5	38
8	Mechanism of interference by haemolysis in the cardiac troponin T immunoassay. Annals of Clinical Biochemistry, 2006, 43, 49-56.	0.8	32
9	Clinical evaluation and treatment of phaeochromocytoma. Annals of Clinical Biochemistry, 2018, 55, 34-48.	0.8	32
10	Measurement of teicoplanin by liquid chromatography-tandem mass spectrometry: development of a novel method. Annals of Clinical Biochemistry, 2012, 49, 475-481.	0.8	23
11	Acute fatal metabolic complications in alkaptonuria. Journal of Inherited Metabolic Disease, 2016, 39, 203-210.	1.7	23
12	Potential problems with using deuterated internal standards for liquid chromatography-tandem mass spectrometry. Annals of Clinical Biochemistry, 2013, 50, 274-274.	0.8	22
13	The phenomenon of seasonal pseudohypokalemia: Effects of ambient temperature, plasma glucose and role for sodium–potassium-exchanging-ATPase. Clinical Biochemistry, 2009, 42, 813-818.	0.8	21
14	Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects. Clinical Chemistry and Laboratory Medicine, 2015, 53, e81-3.	1.4	21
15	Alkaptonuria – Many questions answered, further challenges beckon. Annals of Clinical Biochemistry, 2020, 57, 106-120.	0.8	21
16	Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging. Metabolomics, 2019, 15, 68.	1.4	20
17	Nitisinone causes acquired tyrosinosis in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 1014-1023.	1.7	20
18	Fetal hemoglobin: assessment of glycation and acetylation status by electrospray ionization mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1230-8.	1.4	19

ANDREW S DAVISON

#	Article	IF	CITATIONS
19	Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. Journal of Inherited Metabolic Disease, 2020, 43, 737-747.	1.7	18
20	Evaluation of the Mitra microsampling device for use with key urinary metabolites in patients with Alkaptonuria. Bioanalysis, 2018, 10, 1919-1932.	0.6	17
21	A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria. Clinical Chemistry, 2019, 65, 530-539.	1.5	17
22	Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4ÂWeeks of Treatment. JIMD Reports, 2017, 41, 1-10.	0.7	16
23	Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. Scientific Reports, 2019, 9, 10024.	1.6	16
24	Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone. Molecular Genetics and Metabolism, 2018, 125, 135-143.	0.5	15
25	The Consequences of Valproate Overdose. Clinical Chemistry, 2011, 57, 1233-1237.	1.5	14
26	The nutritional status of people with alkaptonuria: An exploratory analysis suggests a protein/energy dilemma. JIMD Reports, 2020, 53, 45-60.	0.7	14
27	Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone. JIMD Reports, 2018, 41, 109-117.	0.7	13
28	Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre. JIMD Reports, 2020, 55, 75-87.	0.7	13
29	Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism. Genes and Diseases, 2022, 9, 1129-1142.	1.5	13
30	Assessment of endogenous, oral and inhaled steroid cross-reactivity in the Roche cortisol immunoassay. Annals of Clinical Biochemistry, 2014, 51, 503-506.	0.8	12
31	Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LCâ€QTOFâ€MS. JIMD Reports, 2019, 48, 67-74.	0.7	11
32	Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole. Annals of Clinical Biochemistry, 2017, 54, 686-695.	0.8	10
33	Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone. Data in Brief, 2018, 20, 1620-1628.	0.5	10
34	Liquid chromatography tandem mass spectrometry for plasma metadrenalines. Clinica Chimica Acta, 2019, 495, 512-521.	0.5	9
35	Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. Journal of Clinical Medicine, 2021, 10, 5755.	1.0	9
36	The gonadotrophic response of Royal Marines during an operational deployment in Afghanistan. Andrology, 2015, 3, 293-297.	1.9	7

ANDREW S DAVISON

#	Article	IF	CITATIONS
37	Diabetes in pregnancy: Effect on glycation and acetylation of the different chains of fetal and maternal hemoglobin. Clinical Biochemistry, 2011, 44, 198-202.	0.8	6
38	Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria. Molecular Genetics and Metabolism Reports, 2022, 30, 100846.	0.4	6
39	Longâ€ŧerm low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression. JIMD Reports, 2022, 63, 221-230.	0.7	6
40	Temporal adaptations in the phenylalanine/tyrosine pathway and related factors during nitisinone-induced tyrosinaemia in alkaptonuria. Molecular Genetics and Metabolism, 2022, , .	0.5	6
41	Can lithium-heparin plasma be used for protein electrophoresis and paraprotein identification?. Annals of Clinical Biochemistry, 2006, 43, 31-34.	0.8	5
42	Urinary free metanephrines and suitability of available quality control material. Clinica Chimica Acta, 2013, 424, 83-84.	0.5	5
43	The impact of calcium assay change on a local adjusted calcium equation. Annals of Clinical Biochemistry, 2016, 53, 292-294.	0.8	4
44	Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria. Metabolites, 2022, 12, 477.	1.3	4
45	Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?. Molecular Genetics and Metabolism Reports, 2020, 23, 100588.	0.4	3
46	Liquid chromatography tandem mass spectrometry: challenges in introducing published methods into the clinical laboratory. Annals of Clinical Biochemistry, 2018, 55, 404-405.	0.8	1
47	The severity of pseudohyperkalaemia is not dependent upon the stage of chronic kidney disease: a prospective study. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1005-9.	1.4	0
48	A 12-cm Mass with No Symptoms and Unremarkable Laboratory Results. Clinical Chemistry, 2013, 59, 1561-1564.	1.5	0